| Brittney Marie Barber, FNP-BC | |
|
7065 Sydney Curv, Montgomery, AL 36117-3509 | |
| (334) 495-2600 | |
| (334) 495-2604 |
| Full Name | Brittney Marie Barber |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 7065 Sydney Curv, Montgomery, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013514256 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 1-153975 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Medical Center South | Montgomery, AL | Hospital |
| Baptist Medical Center East | Montgomery, AL | Hospital |
| Prattville Baptist Hospital | Prattville, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital City Gastroenterology, Pc | 6800887530 | 6 |
News Archive
Neuroinformatics scientists at Osnabrück University and data specialists at Forschungszentrum Jülich are releasing new model results daily to forecast COVID-19 infections.
Canadian women diagnosed with early breast cancer lose, on average, more than a quarter of their typical income during the first 12 months after their diagnosis, according to a study published online February 26 in the Journal of the National Cancer Institute.
Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 1 days ago
| Entity Name | Capital City Gastroenterology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073587523 PECOS PAC ID: 6800887530 Enrollment ID: O20040521000235 |
News Archive
Neuroinformatics scientists at Osnabrück University and data specialists at Forschungszentrum Jülich are releasing new model results daily to forecast COVID-19 infections.
Canadian women diagnosed with early breast cancer lose, on average, more than a quarter of their typical income during the first 12 months after their diagnosis, according to a study published online February 26 in the Journal of the National Cancer Institute.
Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 1 days ago
| Entity Name | Paragon Contracting Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225071459 PECOS PAC ID: 3971417825 Enrollment ID: O20050218000756 |
News Archive
Neuroinformatics scientists at Osnabrück University and data specialists at Forschungszentrum Jülich are releasing new model results daily to forecast COVID-19 infections.
Canadian women diagnosed with early breast cancer lose, on average, more than a quarter of their typical income during the first 12 months after their diagnosis, according to a study published online February 26 in the Journal of the National Cancer Institute.
Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 1 days ago
| Entity Name | Emergency Services Of Montgomery Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528310323 PECOS PAC ID: 6608028204 Enrollment ID: O20121205000519 |
News Archive
Neuroinformatics scientists at Osnabrück University and data specialists at Forschungszentrum Jülich are releasing new model results daily to forecast COVID-19 infections.
Canadian women diagnosed with early breast cancer lose, on average, more than a quarter of their typical income during the first 12 months after their diagnosis, according to a study published online February 26 in the Journal of the National Cancer Institute.
Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brittney Marie Barber, FNP-BC 7624 Wigmore St, Montgomery, AL 36116-6781 Ph: (334) 220-8623 | Brittney Marie Barber, FNP-BC 7065 Sydney Curv, Montgomery, AL 36117-3509 Ph: (334) 495-2600 |
News Archive
Neuroinformatics scientists at Osnabrück University and data specialists at Forschungszentrum Jülich are releasing new model results daily to forecast COVID-19 infections.
Canadian women diagnosed with early breast cancer lose, on average, more than a quarter of their typical income during the first 12 months after their diagnosis, according to a study published online February 26 in the Journal of the National Cancer Institute.
Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
› Verified 1 days ago
Kathryn Nicole Logan, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4371 Narrow Lane Rd Ste 205, Montgomery, AL 36116 Phone: 334-747-7780 Fax: 334-747-7790 | |
Mrs. Katelyn Perry Barnes, NP-C, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 488 Saint Lukes Dr, Montgomery, AL 36117 Phone: 334-288-7808 Fax: 334-288-8089 | |
Christine Morris, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 7125 University Ct, Montgomery, AL 36117 Phone: 334-239-2622 | |
Dr. Morgan Renee Carter, DNP, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4145 Carmichael Rd, Montgomery, AL 36106 Phone: 334-273-7000 Fax: 334-273-2228 | |
Kaitlyn Wells, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 6940 Winton Blount Blvd, Montgomery, AL 36117 Phone: 334-279-9211 | |
Angela K Rayborn, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1725 W 4th St # Na, Montgomery, AL 36106 Phone: 334-262-2071 |